JP2021525245A5 - - Google Patents

Info

Publication number
JP2021525245A5
JP2021525245A5 JP2020565341A JP2020565341A JP2021525245A5 JP 2021525245 A5 JP2021525245 A5 JP 2021525245A5 JP 2020565341 A JP2020565341 A JP 2020565341A JP 2020565341 A JP2020565341 A JP 2020565341A JP 2021525245 A5 JP2021525245 A5 JP 2021525245A5
Authority
JP
Japan
Prior art keywords
vector
polynucleotide
promoter
use according
aav2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565341A
Other languages
English (en)
Japanese (ja)
Other versions
JP7587423B2 (ja
JP2021525245A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033616 external-priority patent/WO2019226832A1/en
Publication of JP2021525245A publication Critical patent/JP2021525245A/ja
Publication of JP2021525245A5 publication Critical patent/JP2021525245A5/ja
Application granted granted Critical
Publication of JP7587423B2 publication Critical patent/JP7587423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565341A 2018-05-22 2019-05-22 アルツハイマー病のための遺伝子治療 Active JP7587423B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862675003P 2018-05-22 2018-05-22
US62/675,003 2018-05-22
PCT/US2019/033616 WO2019226832A1 (en) 2018-05-22 2019-05-22 Gene therapy for alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2021525245A JP2021525245A (ja) 2021-09-24
JP2021525245A5 true JP2021525245A5 (cg-RX-API-DMAC7.html) 2022-05-26
JP7587423B2 JP7587423B2 (ja) 2024-11-20

Family

ID=68617210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565341A Active JP7587423B2 (ja) 2018-05-22 2019-05-22 アルツハイマー病のための遺伝子治療

Country Status (8)

Country Link
US (1) US12497608B2 (cg-RX-API-DMAC7.html)
EP (1) EP3796980A4 (cg-RX-API-DMAC7.html)
JP (1) JP7587423B2 (cg-RX-API-DMAC7.html)
CN (1) CN112739419A (cg-RX-API-DMAC7.html)
AU (1) AU2019272848A1 (cg-RX-API-DMAC7.html)
CA (1) CA3100946A1 (cg-RX-API-DMAC7.html)
IL (1) IL278813A (cg-RX-API-DMAC7.html)
WO (1) WO2019226832A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019272848A1 (en) 2018-05-22 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
CA3141712A1 (en) 2019-05-24 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
AU2020393917A1 (en) * 2019-11-29 2022-06-23 Paros Bio, Inc. Gene therapy for neurodegenerative disorders
US20240141408A1 (en) * 2021-06-10 2024-05-02 The Brigham And Women’S Hospital, Inc. Cell-based assay for identification of activators of gamma-secretase
JP2024534961A (ja) * 2021-09-10 2024-09-26 アルナイラム ファーマシューティカルズ, インコーポレイテッド 拡大したエンドソームによって特徴付けられる疾患を処置または予防するためのAPP iRNA組成物およびその使用方法
CN116024270B (zh) * 2021-12-27 2025-07-22 中国科学院昆明动物研究所 一种app/psen1双转基因阿尔茨海默病树鼩模型的建立方法
CN115125244A (zh) * 2022-05-14 2022-09-30 吉林大学 构建阿尔兹海默症的兔模型方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JPH10501686A (ja) 1994-04-13 1998-02-17 ザ ロックフェラー ユニヴァーシティ 神経系の細胞へのdnaのaav仲介送達
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
WO1997027296A1 (en) 1996-01-26 1997-07-31 Hsc Research And Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
AR020107A1 (es) * 1998-07-09 2002-04-10 Boehringer Ingelheim Pharma Metodo para identificar una sustancia capaz de reducir o eliminar la actividad de la presenilinasa, las sustancias identificables con dicho metodo, el usode estas ultimas en la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y las composiciones farmaceuticas que
JP2002520055A (ja) * 1998-07-16 2002-07-09 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトプレセニリン関連タンパク質
US6979537B2 (en) 2000-01-10 2005-12-27 Scios, Inc. Methods for identifying inhibitors of neuronal degeneration
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7271313B2 (en) 2003-04-09 2007-09-18 The Brigham And Women's Hospital, Inc. Presenilin-deficient mouse model of age-dependent neurodegeneration and cognitive loss
CA2528963A1 (en) 2003-06-27 2005-01-13 Sirna Therapeutics, Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
WO2005037226A2 (en) 2003-10-17 2005-04-28 Georgia Tech Research Corporation Genetically engineered enteroendocrine cells for treating glucose-related metabolic disorders
CA2541523A1 (en) 2003-10-21 2005-05-06 Applied Research Systems Ars Holding N.V. Minimal dna sequence acting as a chromatin insulator and its use in protein expression
WO2005096781A2 (en) 2004-04-06 2005-10-20 University Of Massachusetts Methods and compositions for treating gain-of-function disorders using rna interference
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
CN101031658A (zh) 2004-05-26 2007-09-05 罗塞塔金诺米克斯有限公司 病毒和病毒相关mirna及其用途
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
WO2009042727A1 (en) * 2007-09-24 2009-04-02 The Johns Hopkins University Immediate early gene arc interacts with endocytic machinery and regulates the trafficking and function of presenilin
AU2010316982B2 (en) 2009-11-09 2013-09-12 Genepod Therapeutics Ab Novel viral vector construct for neuron specific continuous DOPA synthesis in vivo
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
CN103816540B (zh) 2012-11-16 2018-01-02 中国科学院上海生命科学研究院 降低β‑抑制蛋白1与APH‑1蛋白的结合的物质在制备防治神经退行性疾病药物中的应用
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
WO2015006743A1 (en) * 2013-07-12 2015-01-15 The Children's Hospital Of Philadelphia Aav vector and assay for anti-aav (adeno-associated virus) neutralizing antibodies
GB201404470D0 (en) 2014-03-13 2014-04-30 Ucl Business Plc Therapeutic methods and materials
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
US10350245B2 (en) 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
EP3270960A4 (en) 2015-03-20 2018-08-08 Bluebird Bio, Inc. Vector formulations
US10568516B2 (en) * 2015-06-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CA3025626A1 (en) 2016-05-27 2017-11-30 Transcriptx, Inc. Treatment of primary ciliary dyskinesia with synthetic messenger rna
WO2018045022A1 (en) 2016-08-30 2018-03-08 University Of South Florida Adipose derived stem cell exosomes and uses thereof
WO2018140532A1 (en) 2017-01-24 2018-08-02 Fred Hutchinson Cancer Research Center Systems and methods for hematopoietic cell expansion utilizing hydrogels
US11713470B2 (en) 2017-03-20 2023-08-01 University of Pittsburgh—of the Commonwealth System of Higher Education Targeted gene therapies for pain and other neuro-related disorders
US11015204B2 (en) 2017-05-31 2021-05-25 Arcturus Therapeutics, Inc. Synthesis and structure of high potency RNA therapeutics
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
AU2019272848A1 (en) 2018-05-22 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
CA3141712A1 (en) 2019-05-24 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
AU2020393917A1 (en) 2019-11-29 2022-06-23 Paros Bio, Inc. Gene therapy for neurodegenerative disorders
EP4096786A4 (en) 2020-01-31 2024-04-10 Paros Bio, Inc. GENE THERAPY FOR NEURODEGENERATIVE DISORDERS USING POLYNUCLEOTIDE SILENCING AND REPLACEMENT

Similar Documents

Publication Publication Date Title
JP2020533959A5 (cg-RX-API-DMAC7.html)
AU2023217698A1 (en) Aav capsid variants and uses thereof
JP2022535749A5 (cg-RX-API-DMAC7.html)
JP2020500526A5 (cg-RX-API-DMAC7.html)
JP2021505133A5 (cg-RX-API-DMAC7.html)
JP2020519629A5 (cg-RX-API-DMAC7.html)
JP7616995B2 (ja) 神経変性疾患のための遺伝子治療
EP3701030A1 (en) Gene therapies for neurodegenerative disease
JP2021512649A5 (cg-RX-API-DMAC7.html)
JP2022533451A5 (cg-RX-API-DMAC7.html)
JP2013531471A5 (cg-RX-API-DMAC7.html)
JP2023537980A5 (cg-RX-API-DMAC7.html)
JP2019537576A5 (cg-RX-API-DMAC7.html)
FI3373980T3 (fi) Menetelmiä lihasdystrofian hoitamiseksi
JP2023500793A5 (cg-RX-API-DMAC7.html)
CN112739419A (zh) 用于阿尔茨海默症的基因治疗
JP2023059858A5 (cg-RX-API-DMAC7.html)
JP7686573B6 (ja) アルツハイマー病のための遺伝子治療
JP2024543253A5 (cg-RX-API-DMAC7.html)
JP2022545378A5 (cg-RX-API-DMAC7.html)
JP2025514489A5 (cg-RX-API-DMAC7.html)
JP2023551254A (ja) 神経変性疾患のための遺伝子治療
JP2022552014A5 (cg-RX-API-DMAC7.html)
JP2024515629A5 (cg-RX-API-DMAC7.html)
JP2023502474A5 (cg-RX-API-DMAC7.html)